The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Incretin-Based Drugs Market Projected To Reach By 2030?
The incretin-based drugs market has experienced substantial growth in recent years. It is projected to increase from $27.83 billion in 2025 to $29.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. This expansion during the historic period can be attributed to factors such as the prevalence of type 2 diabetes, insulin resistance rates, lifestyle-related metabolic disorders, the adoption of endocrinology drugs, and hospital diabetes programs.
The incretin-based drugs market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is attributable to factors such as the global obesity epidemic, the increasing demand for weight management drugs, advancements in long-acting incretin therapies, a shift towards personalized diabetes care, and an emphasis on preventive metabolic health. Key trends expected over the forecast period encompass the swift uptake of GLP-1 receptor agonists, the broadening of obesity management indications, an increase in the application of oral incretin therapies, the emergence of more combination therapy approaches, and enhanced patient adherence facilitated by weekly dosing regimens.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp
Which Factors Are Influencing The Growth Of The Incretin-Based Drugs Market?
The escalating occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market. This chronic metabolic condition is characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. The widespread incidence of Type 2 diabetes is primarily attributed to poor dietary choices and sedentary lifestyles, which contribute to insulin resistance and diminish the body’s ability to regulate blood sugar. Incretin-based drugs offer a therapeutic approach for type 2 diabetes by enhancing insulin release after meals and decreasing glucagon production, thereby helping to reduce blood sugar. These medications also slow stomach emptying and curb appetite, assisting in glucose control and weight loss. For example, in June 2024, the National Health Service, a UK-based government department, stated that in 2023, about 549,000 more people in England faced a risk of developing type 2 diabetes, pushing the total number with pre-diabetes to over 3.6 million, marking a nearly 20% increase from 2022. Thus, the increasing prevalence of type 2 diabetes mellitus is a key factor stimulating the growth of the incretin-based drugs market.
Which Segment Types Are Examined In The Incretin-Based Drugs Market Segment Study?
The incretin-based drugs market covered in this report is segmented –
1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Type 2 Diabetes, Obesity, Other Applications
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
What Trends Are Transforming The Incretin-Based Drugs Market?
Leading companies active in the incretin-based drugs market are prioritizing the development of generic drug versions to supply more effective and patient-friendly therapeutic options for type 2 diabetes. A generic medication possesses the identical active constituents, strength, dosage format, and administration route as a branded drug, but it is distributed under its chemical identity without brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched the inaugural generic variant of Victoza (liraglutide) injection, 6 mg/mL, in the United States. It obtained Food and Drug Administration (FDA) approval. The product was indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst current shortages of GLP-1 medications.
Which Players Are Part Of The Competitive Landscape Of The Incretin-Based Drugs Market?
Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation
Get The Full Incretin-Based Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report
Which Region Leads The Incretin-Based Drugs Market In Overall Market Size?
North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Incretin-Based Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report
Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Pharmaceuticals Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model